> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 receptor agonists and lung cancer in type 2 diabetes with pulmonary nodules
- URL: https://www.coios.me/glp-1-receptor-agonists-and-lung-cancer-in-type-2-diabetes/
- Published: 2026-11-15T11:39:53.000Z
- Updated: 2026-11-15T12:24:54.000Z
- Description: GLP-1 receptor agonists were linked to fewer lung cancers than metformin, but genetic and SGLT2 inhibitor comparisons gave no support.
- Author: Daniel Ryan
- Tags: Health today, Cancer, Obesity, diabetes and GLP-1, What linked data reveals, United States, #peer-reviewed, #refines, #item, #source-2026-11, #score-65

This target trial emulation compared adults with type 2 diabetes and a pulmonary nodule starting GLP-1 receptor agonists or metformin. Among 12,622 matched pairs, lung cancer incidence was 1.60% with GLP-1 receptor agonists. With metformin it was 2.14% (HR 0.77, 95% CI 0.64-0.92). The hazard ratio was 0.77 (0.54-1.09) at a 365-day landmark and 0.85 (0.69-1.05) against SGLT2 inhibitors. Cis-Mendelian randomisation, using gene variants that alter GLP1R expression, found no link with lung cancer. The design is observational and open to residual confounding, and outcomes cover only days 90 to 1,095 after starting treatment.

*Why it is interesting: The study pairs a trial emulation with genetic evidence to test an observational drug–cancer signal. Neither the SGLT2 inhibitor comparison nor the genetic analysis supported the lower lung cancer incidence seen against metformin.*

Source

[Cancer Epidemiology, Biomarkers & Prevention, 13 November 2026](https://doi.org/10.1158/1055-9965.epi-26-0970?ref=coios.me)

Paper

Glucagon-like peptide-1 receptor agonists and lung cancer risk in patients with type 2 diabetes and pulmonary nodules

Authors

Yang TL, Jhou HJ, Chang WC, Chen HY, Chen PH, Lee CH

DOI

10.1158/1055-9965.epi-26-0970

Type

Peer-reviewed article

Design

Target trial emulation in the TriNetX federated network, 12,622 propensity-matched pairs (51 covariates) of new GLP-1RA vs metformin users with type 2 diabetes and a coded pulmonary nodule, outcomes day 90-1,095, with active comparators (DPP-4, SGLT2), landmark analyses, negative controls and drug-target cis-Mendelian randomisation in three GWAS consortia

Verdict

Refines prior evidence

Driver

[Cancer](https://www.coios.me/d-cancer/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)

Driver

[What linked data reveals](https://www.coios.me/d-linked-data/)